泰合健康(000790.SZ)發佈半年報淨利潤升287.08%至3685.44萬元
格隆匯8月19日丨泰合健康(000790.SZ)發佈2019年半年度報告，實現營業收入約3.42億元，同比增長29.81%；歸屬於上市公司股東的淨利潤約3685.44萬元，同比增長287.08%；歸屬於上市公司股東的扣除非經常性損益的淨利潤約3665.21萬元同比增長371.57%；基本每股收益0.0598元。
隨着國民經濟的發展、人民生活水平的提高，以及人口老齡化的加劇、城鎮化推進、醫療衞生體系逐步完善等因素的影響，我國醫藥行業市場總量逐年增長。2018年以來，醫療衞生體制改革和頂層設計發生了深刻變化，政府機構進行了新一輪的改革，國家衞生健康委員會、國家醫療保障局成立，國家藥品監督管理局組建成立，由國家市場監督管理總局管理，這將使三醫聯動執行體系更具效率。2019年，國家醫改政策持續深化推進，醫保控費、仿製藥一致性評價、“4+7”藥品國家集中採購、DRGs和國家重點監控藥品目錄等政策陸續實施，對傳統醫藥行業市場格局帶來巨大沖擊。總體上，醫藥行業市場機遇與挑戰並存，未來契合醫保方向的品種和企業將獲得更好的發展機會，創新轉型趨勢已勢不可擋。
公司屬於醫藥製造業，在醫藥行業供給側結構性改革持續深入，行業監管日益嚴格，各項政策法規密集出台的環境下，公司積極應對市場變革帶來的挑戰，優化資源配置，持續加強市場拓展力度，經營業績實現穩健增長，經營品質持續提升,核心競爭力穩步增強。
報告期，公司實現營業總收入約3.42億元，同比增加7862.74萬元，上升29.81%，其中中西成藥產業實現主營業務收入約3.20億元，同比增加7214.95萬元，增長29.17%；生物製藥產業實現主營業務收入359.35萬元，同比增加141.81萬元，增長65.19%；鋼構產業實現主營業務收入1328.15萬元，同比增加255.84萬元，增長23.86%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
